Incannex Healthcare Limited (IXHL)
USD 0.58
(-1.69%)
USD 0.58
(-1.69%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 373 Thousand USD | -28.41% |
| 2023 | 520.77 Thousand AUD | 0.0% |
| 2022 | - AUD | 0.0% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | -100.0% |
| 2019 | 65 Thousand AUD | -67.5% |
| 2018 | 200 Thousand AUD | -49.68% |
| 2017 | 397.45 Thousand AUD | 7.53% |
| 2016 | 369.62 Thousand AUD | -62.81% |
| 2015 | 993.77 Thousand AUD | 7.37% |
| 2014 | 925.56 Thousand AUD | -37.07% |
| 2013 | 1.47 Million AUD | 55.09% |
| 2012 | 948.34 Thousand AUD | 13.9% |
| 2011 | 832.61 Thousand AUD | -56.04% |
| 2010 | 1.89 Million AUD | -70.07% |
| 2009 | 6.32 Million AUD | 5860.46% |
| 2008 | 106.19 Thousand AUD | 32.14% |
| 2007 | 80.36 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 470 Thousand USD | -9.79% |
| 2024 Q3 | 409 Thousand USD | -12.98% |
| 2024 Q4 | 373 Thousand USD | -20.64% |
| 2023 Q4 | 520.77 Thousand AUD | 0.0% |
| 2023 FY | 520.77 Thousand AUD | 0.0% |
| 2023 Q2 | 157.82 Thousand AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 FY | - AUD | 0.0% |
| 2022 Q4 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2021 FY | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 FY | - AUD | -100.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2019 FY | 65 Thousand AUD | -67.5% |
| 2019 Q4 | 65 Thousand AUD | 0.0% |
| 2019 Q2 | 100 Thousand AUD | 0.0% |
| 2018 FY | 200 Thousand AUD | -49.68% |
| 2018 Q2 | 200 Thousand AUD | 0.0% |
| 2018 Q4 | 200 Thousand AUD | 0.0% |
| 2017 FY | 397.45 Thousand AUD | 7.53% |
| 2017 Q4 | 397.45 Thousand AUD | 0.0% |
| 2017 Q2 | 382.94 Thousand AUD | 0.0% |
| 2016 Q4 | 369.62 Thousand AUD | 300.0% |
| 2016 FY | 369.62 Thousand AUD | -62.81% |
| 2016 Q3 | 92.4 Thousand AUD | -87.87% |
| 2016 Q2 | 761.88 Thousand AUD | 206.67% |
| 2016 Q1 | 248.44 Thousand AUD | -75.0% |
| 2015 Q1 | 231.39 Thousand AUD | -75.0% |
| 2015 Q4 | 993.77 Thousand AUD | 300.0% |
| 2015 Q2 | 983.11 Thousand AUD | 324.87% |
| 2015 Q3 | 248.44 Thousand AUD | -74.73% |
| 2015 FY | 993.77 Thousand AUD | 7.37% |
| 2014 FY | 925.56 Thousand AUD | -37.07% |
| 2014 Q1 | 367.7 Thousand AUD | -75.0% |
| 2014 Q2 | 895.68 Thousand AUD | 143.59% |
| 2014 Q3 | 231.39 Thousand AUD | -74.17% |
| 2014 Q4 | 925.56 Thousand AUD | 300.0% |
| 2013 FY | 1.47 Million AUD | 55.09% |
| 2013 Q4 | 1.47 Million AUD | 300.0% |
| 2013 Q3 | 367.7 Thousand AUD | -74.99% |
| 2013 Q2 | 1.47 Million AUD | 520.15% |
| 2013 Q1 | 237.08 Thousand AUD | -75.0% |
| 2012 Q2 | 892.27 Thousand AUD | 328.66% |
| 2012 FY | 948.34 Thousand AUD | 13.9% |
| 2012 Q4 | 948.34 Thousand AUD | 300.0% |
| 2012 Q3 | 237.08 Thousand AUD | -73.43% |
| 2012 Q1 | 208.15 Thousand AUD | -75.0% |
| 2011 Q1 | 466.93 Thousand AUD | -75.35% |
| 2011 Q4 | 832.61 Thousand AUD | 300.0% |
| 2011 FY | 832.61 Thousand AUD | -56.04% |
| 2011 Q3 | 208.15 Thousand AUD | -89.42% |
| 2011 Q2 | 1.96 Million AUD | 321.23% |
| 2010 Q4 | 1.89 Million AUD | 305.65% |
| 2010 Q2 | 6.35 Million AUD | 301.91% |
| 2010 Q1 | 1.58 Million AUD | -75.0% |
| 2010 FY | 1.89 Million AUD | -70.07% |
| 2010 Q3 | 466.93 Thousand AUD | -92.66% |
| 2009 Q4 | 6.32 Million AUD | 300.0% |
| 2009 Q3 | 1.58 Million AUD | 463.8% |
| 2009 Q2 | 280.66 Thousand AUD | 957.19% |
| 2009 FY | 6.32 Million AUD | 5860.46% |
| 2009 Q1 | 26.54 Thousand AUD | -75.0% |
| 2008 Q2 | 125.7 Thousand AUD | 525.71% |
| 2008 Q4 | 106.19 Thousand AUD | 300.0% |
| 2008 FY | 106.19 Thousand AUD | 32.14% |
| 2008 Q1 | 20.09 Thousand AUD | -75.0% |
| 2008 Q3 | 26.54 Thousand AUD | -78.88% |
| 2007 FY | 80.36 Thousand AUD | 0.0% |
| 2007 Q4 | 80.36 Thousand AUD | 300.01% |
| 2007 Q3 | 20.09 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 97.798% |
| PainReform Ltd. | 86 Thousand USD | -333.721% |
| Alvotech | 1.07 Billion USD | 99.965% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.945% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.882% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 99.623% |
| Journey Medical Corporation | 17.73 Million USD | 97.896% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.855% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.931% |
| Bright Green Corporation | 1.85 Million USD | 79.857% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.936% |
| Embecta Corp. | 1.63 Billion USD | 99.977% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 43.288% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 43.288% |
| SCYNEXIS, Inc. | 15.08 Million USD | 97.527% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 95.493% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | 85.911% |
| Alpha Teknova, Inc. | 30.45 Million USD | 98.775% |
| Safety Shot Inc | 1.54 Million USD | 75.92% |
| Procaps Group, S.A. | 285.93 Million USD | 99.87% |
| Cosmos Health Inc. | 12.42 Million USD | 96.998% |
| Theratechnologies Inc. | 58.96 Million USD | 99.367% |
| Harrow Health, Inc. | 190.5 Million USD | 99.804% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | 38.651% |
| Biofrontera Inc. | 5.39 Million USD | 93.091% |
| DURECT Corporation | 20.74 Million USD | 98.202% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 99.102% |
| Cronos Group Inc. | 2.53 Million USD | 85.315% |
| OptiNose, Inc. | 131.74 Million USD | 99.717% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.948% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 98.973% |
| RedHill Biopharma Ltd. | 1.17 Million USD | 68.201% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 99.687% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 97.976% |
| Radius Health, Inc. | 365.31 Million USD | 99.898% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 93.196% |
| ProPhase Labs, Inc. | 21.38 Million USD | 98.255% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.929% |
| Procaps Group S.A. | 285.93 Million USD | 99.87% |
| TherapeuticsMD, Inc. | 8 Million USD | 95.34% |
| Viatris Inc. | 18.12 Billion USD | 99.998% |
| Rockwell Medical, Inc. | 13.43 Million USD | 97.224% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 97.535% |
| SIGA Technologies, Inc. | 1.46 Million USD | 74.522% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.904% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 99.714% |
| Shineco, Inc. | 29.65 Million USD | 98.742% |
| PetIQ, Inc. | 468.3 Million USD | 99.92% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -523.673% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.913% |
| Alimera Sciences, Inc. | 67.39 Million USD | 99.447% |
| Assertio Holdings, Inc. | 40.91 Million USD | 99.088% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | 65.707% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | 82.127% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 63.896% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 98.946% |
| Hempacco Co., Inc. | 13.72 Million USD | 97.282% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 99.965% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 99.403% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.94% |
| Currenc Group, Inc. | 31.94 Million USD | 98.832% |
| Kamada Ltd. | 8.74 Million USD | 95.737% |
| Indivior PLC | 281.6 Million USD | 99.868% |
| Evoke Pharma, Inc. | 5 Million USD | 92.54% |
| Flora Growth Corp. | 3.67 Million USD | 89.842% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 63.896% |
| Evolus, Inc. | 126.54 Million USD | 99.705% |
| HUTCHMED (China) Limited | 86.13 Million USD | 99.567% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.94% |
| Akanda Corp. | 3.99 Million USD | 90.672% |